Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Oculomucocutaneous syndrome
Introduction
Overview
Overview
Oculomucocutaneous syndrome is characterized by keratoconjunctivitis sicca and by scarring, fibrosis, metaplasia, and shrinkage of the conjunctiva.[1] It is a drug side effect observed in practolol and eperisone. It is speculated that antibodies against drug metabolites cause the syndrome.[2]
References
References
- ↑ Wright, P (Mar 15, 1975). “Untoward effects associated with practolol administration: oculomucocutaneous syndrome”. British Medical Journal. 1 (5958): 595–8. PMC 1672788. PMID 1125623.
- ↑ Amos, HE (Feb 18, 1978). “Possible role of antibody specific for a practolol metabolite in the pathogenesis of oculomucocutaneous syndrome”. British Medical Journal. 1 (6110): 402–4. PMC 1602979. PMID 146533. Unknown parameter
|coauthors=ignored (help)
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]